Blog Articles
A scientific hub to keep you informed about our latest research and company updates.
How do you build the right immunotoxicity assessment strategy for your nonclinical safety GLP program?
Your compound has shown efficacy in a preclinical disease model – now what? Moving from exploratory studies to GLP toxicology studies
Plasma NfL, p-tau217, or Aβ42/40: Which Alzheimer’s disease biomarkers should you include in your preclinical efficacy study?
Transgenic Amyloid, Tau, Seeding, or combined Amyloid/Tau pathology mouse models — which is the right one for your drug development program?
Morris Water Maze, Rotarod and beyond: How do you build a comprehensive behavioral test battery when outsourcing your preclinical Alzheimer’s disease efficacy study?
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
Top 4 Multi-Organ-on-a-Chip TissUse Assays and Why You Should Include them in Your Preclinical Research in 2025
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Introduction to InnoSer’s Preclinical Epilepsy Research CRO Platform
info@innoserlaboratories.com